Thioredoxin 1 modulates apoptosis induced by bioactive compounds in prostate cancer cells

Redox Biology

Volumn 12, Issue , 2017, Pages 634-647

  Rodriguez Garcia, Aida ^a   Hevia, David ^a,b   Mayo, Juan C ^a   Gonzalez Menendez, Pedro ^a   Coppo, Lucia ^c   Lu, Jun ^c   Holmgren, Arne ^c   Sainz, Rosa M ^a  

^a DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^b Research and Development Department   (Spain)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Apoptosis; Prostate cancer; Redox signaling; Thioredoxin; Thioredoxin reductase; TXNIP

Indexed keywords

APOPTOSIS SIGNAL REGULATING KINASE 1; COPPER ZINC SUPEROXIDE DISMUTASE; CURCUMIN; MELATONIN; MESSENGER RNA; NATURAL PRODUCT; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; RESVERATROL; SILIBININ; THIOREDOXIN 1; THIOREDOXIN INTERACTING PROTEIN; CARRIER PROTEIN; SILYMARIN; STILBENE DERIVATIVE; THIOREDOXIN; TXN PROTEIN, HUMAN; TXNIP PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ASSAY; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC50; MALE; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; CELL SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; PROSTATE TUMOR; TUMOR CELL LINE;

APOPTOSIS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; CURCUMIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MELATONIN; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; SILYMARIN; STILBENES; THIOREDOXINS;

EID: 85017099116     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2017.03.025     Document Type: Article

References (66)

1. [1] Halliwell, B., Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18 (2001), 685–716.
2. [2] Sosa, V., Moline, T., Somoza, R., Paciucci, R., Kondoh, H., ME, L.L., Oxidative stress and cancer: an overview. Ageing Res. Rev. 12 (2013), 376–390.
3. [3] Wu, W.S., The signaling mechanism of ROS in tumor progression. Cancer Metastas. Rev. 25 (2006), 695–705.
4. [4] Benhar, M., Engelberg, D., Levitzki, A., ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep. 3 (2002), 420–425.
5. [5] Pelicano, H., Carney, D., Huang, P., ROS stress in cancer cells and therapeutic implications. Drug Resist. Update 7 (2004), 97–110.
6. [6] Arnér, E.S., Holmgren, A., Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. 267 (2000), 6102–6109.
7. [7] Hayashi, T., Ueno, Y., Okamoto, T., Oxidoreductive regulation of nuclear factor kappa B. Involvement of a cellular reducing catalyst thioredoxin. J. Biol. Chem. 268 (1993), 11380–11388.
8. [8] Hirota, K., Matsui, M., Iwata, S., Nishiyama, A., Mori, K., Yodoi, J., AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc. Natl. Acad. Sci. USA 94 (1997), 3633–3638.
9. [9] Saitoh, M., Nishitoh, H., Fujii, M., Takeda, K., Tobiume, K., Sawada, Y., Kawabata, M., Miyazono, K., Ichijo, H., Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 17 (1998), 2596–2606.
10. [10] Iriyama, T., Takeda, K., Nakamura, H., Morimoto, Y., Kuroiwa, T., Mizukami, J., Umeda, T., Noguchi, T., Naguro, I., Nishitoh, H., Saegusa, K., Tobiume, K., Homma, T., Shimada, Y., Tsuda, H., Aiko, S., Imoto, I., Inazawa, J., Chida, K., Kamei, Y., Kozuma, S., Taketani, Y., Matsuzawa, A., Ichijo, H., ASK1 and ASK2 differentially regulate the counteracting roles of apoptosis and inflammation in tumorigenesis. EMBO J. 28 (2009), 843–853.
11. [11] Zhang, R., Al-Lamki, R., Bai, L., Streb, J.W., Miano, J.M., Bradley, J., Min, W., Thioredoxin-2 inhibits mitochondria-located ASK1-mediated apoptosis in a JNK-independent manner. Circ. Res. 94 (2004), 1483–1491.
12. [12] Ferlay, J., Parkin, D.M., Steliarova-Foucher, E., Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 46 (2010), 765–781.
13. [13] Shukla, S., Gupta, S., Dietary agents in the chemoprevention of prostate cancer. Nutr. Cancer 53 (2005), 18–32.
14. [14] Deeb, D., Xu, Y.X., Jiang, H., Gao, X., Janakiraman, N., Chapman, R.A., Gautam, S.C., Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Mol. Cancer Ther. 2 (2003), 95–103.
15. [15] Gill, C., Walsh, S.E., Morrissey, C., Fitzpatrick, J.M., Watson, R.W., Resveratrol sensitizes androgen independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms. Prostate 67 (2007), 1641–1653.
16. [16] Dhanalakshmi, S., Agarwal, P., Glode, L.M., Agarwal, R., Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin- and carboplatin-induced growth inhibition and apoptotic death. Int. J. Cancer J. Int. Cancer 106 (2003), 699–705.
17. [17] Sainz, R.M., Reiter, R.J., Tan, D.X., Roldan, F., Natarajan, M., Quiros, I., Hevia, D., Rodriguez, C., Mayo, J.C., Critical role of glutathione in melatonin enhancement of tumor necrosis factor and ionizing radiation-induced apoptosis in prostate cancer cells in vitro. J. Pineal Res. 45 (2008), 258–270.
18. [18] Reiter, R.J., Tan, D.X., Melatonin: an antioxidant in edible plants. Ann. N.Y. Acad. Sci. 957 (2002), 341–344.
19. [19] Harper, C.E., Patel, B.B., Wang, J., Arabshahi, A., Eltoum, I.A., Lamartiniere, C.A., Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis 28 (2007), 1946–1953.
20. [20] Zhou, D.Y., Ding, N., Van Doren, J., Wei, X.C., Du, Z.Y., Conney, A.H., Zhang, K., Zheng, X., Effects of curcumin analogues for inhibiting human prostate cancer cells and the growth of human PC-3 prostate xenografts in immunodeficient mice. Biol. Pharm. Bull. 37 (2014), 1029–1034.
21. [21] Tyagi, A., Bhatia, N., Condon, M.S., Bosland, M.C., Agarwal, C., Agarwal, R., Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells. Prostate 53 (2002), 211–217.
22. [22] Ak, T., Gulcin, I., Antioxidant and radical scavenging properties of curcumin. Chem. Biol. Interact. 174 (2008), 27–37.
23. [23] Khanduja, K.L., Bhardwaj, A., Stable free radical scavenging and antiperoxidative properties of resveratrol compared in vitro with some other bioflavonoids. Indian J. Biochem. Biophys. 40 (2003), 416–422.
24. [24] Tan, D.X., Reiter, R.J., Manchester, L.C., Yan, M.T., El-Sawi, M., Sainz, R.M., Mayo, J.C., Kohen, R., Allegra, M., Hardeland, R., Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr. Top. Med. Chem. 2 (2002), 181–197.
25. [25] Katiyar, S.K., Silymarin and skin cancer prevention: anti-inflammatory, antioxidant and immunomodulatory effects (Review). Int. J. Oncol. 26 (2005), 169–176.
26. [26] Shan, W., Zhong, W., Zhao, R., Oberley, T.D., Thioredoxin 1 as a subcellular biomarker of redox imbalance in human prostate cancer progression. Free Radic. Biol. Med. 49 (2010), 2078–2087.
27. [27] Fanjul-Bolado, P., Queipo, P., Lamas-Ardisana, P.J., Costa-Garcia, A., Manufacture and evaluation of carbon nanotube modified screen-printed electrodes as electrochemical tools. Talanta 74 (2007), 427–433.
28. [28] Bersani, N.A., Merwin, J.R., Lopez, N.I., Pearson, G.D., Merrill, G.F., Protein electrophoretic mobility shift assay to monitor redox state of thioredoxin in cells. Methods Enzymol. 347 (2002), 317–326.
29. [29] Takahashi, N., Hirose, M., Determination of sulfhydryl groups and disulfide bonds in a protein by polyacrylamide gel electrophoresis. Anal. Biochem. 188 (1990), 359–365.
30. [30] Du, Y., Zhang, H., Lu, J., Holmgren, A., Glutathione and glutaredoxin act as a backup of human thioredoxin reductase 1 to reduce thioredoxin 1 preventing cell death by aurothioglucose. J. Biol. Chem. 287 (2012), 38210–38219.
31. [31] E.S. Arner, A. Holmgren, Measurement of thioredoxin and thioredoxin reductase. Current protocols in toxicology/editorial board, Mahin D. Maines Chapter 7:Unit 7 4, 2001.
32. [32] Rodriguez-Garcia, A., Mayo, J.C., Hevia, D., Quiros-Gonzalez, I., Navarro, M., Sainz, R.M., Phenotypic changes caused by melatonin increased sensitivity of prostate cancer cells to cytokine-induced apoptosis. J. Pineal Res. 54 (2013), 33–45.
33. [33] Hevia, D., Mayo, J.C., Tan, D.X., Rodriguez-Garcia, A., Sainz, R.M., Melatonin enhances photo-oxidation of 2′,7′-dichlorodihydrofluorescein by an antioxidant reaction that renders N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK). PLoS One, 9, 2014, e109257.
34. [34] Luo, H., Yang, A., Schulte, B.A., Wargovich, M.J., Wang, G.Y., Resveratrol induces premature senescence in lung cancer cells via ROS-mediated DNA damage. PLoS One, 8, 2013, e60065.
35. [35] Thayyullathil, F., Chathoth, S., Hago, A., Patel, M., Galadari, S., Rapid reactive oxygen species (ROS) generation induced by curcumin leads to caspase-dependent and -independent apoptosis in L929 cells. Free Radic. Biol. Med. 45 (2008), 1403–1412.
36. [36] Takeda, K., Hatai, T., Hamazaki, T.S., Nishitoh, H., Saitoh, M., Ichijo, H., Apoptosis signal-regulating kinase 1 (ASK1) induces neuronal differentiation and survival of PC12 cells. J. Biol. Chem. 275 (2000), 9805–9813.
37. [37] Madan, E., Gogna, R., Kuppusamy, P., Bhatt, M., Mahdi, A.A., Pati, U., SCO2 induces p53-mediated apoptosis by Thr845 phosphorylation of ASK-1 and dissociation of the ASK-1-Trx complex. Mol. Cell. Biol. 33 (2013), 1285–1302.
38. [38] Zhang, X., Zheng, Y., Fried, L.E., Du, Y., Montano, S.J., Sohn, A., Lefkove, B., Holmgren, L., Arbiser, J.L., Holmgren, A., Lu, J., Disruption of the mitochondrial thioredoxin system as a cell death mechanism of cationic triphenylmethanes. Free Radic. Biol. Med. 50 (2011), 811–820.
39. [39] Zi, X., Agarwal, R., Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. Proc. Natl. Acad. Sci. USA 96 (1999), 7490–7495.
40. [40] Sainz, R.M., Mayo, J.C., Tan, D.X., Leon, J., Manchester, L., Reiter, R.J., Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate 63 (2005), 29–43.
41. [41] Dorai, T., Cao, Y.C., Dorai, B., Buttyan, R., Katz, A.E., Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate 47 (2001), 293–303.
42. [42] Sheth, S., Jajoo, S., Kaur, T., Mukherjea, D., Sheehan, K., Rybak, L.P., Ramkumar, V., Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway. PLoS One, 7, 2012, e51655.
43. [43] Harper, C.E., Cook, L.M., Patel, B.B., Wang, J., Eltoum, I.A., Arabshahi, A., Shirai, T., Lamartiniere, C.A., Genistein and resveratrol, alone and in combination, suppress prostate cancer in SV-40 tag rats. Prostate 69 (2009), 1668–1682.
44. [44] Aggarwal, B.B., Shishodia, S., Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol. 71 (2006), 1397–1421.
45. [45] Sharma, O.P., Antioxidant activity of curcumin and related compounds. Biochem. Pharmacol. 25 (1976), 1811–1812.
46. [46] Pinlaor, S., Yongvanit, P., Prakobwong, S., Kaewsamut, B., Khoontawad, J., Pinlaor, P., Hiraku, Y., Curcumin reduces oxidative and nitrative DNA damage through balancing of oxidant-antioxidant status in hamsters infected with Opisthorchis viverrini. Mol. Nutr. Food Res. 53 (2009), 1316–1328.
47. [47] Chanvorachote, P., Pongrakhananon, V., Wannachaiyasit, S., Luanpitpong, S., Rojanasakul, Y., Nimmannit, U., Curcumin sensitizes lung cancer cells to cisplatin-induced apoptosis through superoxide anion-mediated Bcl-2 degradation. Cancer Investig. 27 (2009), 624–635.
48. [48] Vue, B., Chen, Q.H., The potential of flavonolignans in prostate cancer management. Curr. Med. Chem. 23 (2016), 3925–3950.
49. [49] Reiter, R.J., Mayo, J.C., Tan, D.X., Sainz, R.M., Alatorre-Jimenez, M., Qin, L., Melatonin as an antioxidant: under promises but over delivers. J. Pineal Res. 61 (2016), 253–278.
50. [50] Kim, S.J., Miyoshi, Y., Taguchi, T., Tamaki, Y., Nakamura, H., Yodoi, J., Kato, K., Noguchi, S., High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 11 (2005), 8425–8430.
51. [51] Yokomizo, A., Ono, M., Nanri, H., Makino, Y., Ohga, T., Wada, M., Okamoto, T., Yodoi, J., Kuwano, M., Kohno, K., Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res. 55 (1995), 4293–4296.
52. [52] Hirota, K., Murata, M., Sachi, Y., Nakamura, H., Takeuchi, J., Mori, K., Yodoi, J., Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-kappaB. J. Biol. Chem. 274 (1999), 27891–27897.
53. [53] Fang, J., Lu, J., Holmgren, A., Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity. J. Biol. Chem. 280 (2005), 25284–25290.
54. [54] Lu, J., Papp, L.V., Fang, J., Rodriguez-Nieto, S., Zhivotovsky, B., Holmgren, A., Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity. Cancer Res. 66 (2006), 4410–4418.
55. [55] Nishiyama, A., Matsui, M., Iwata, S., Hirota, K., Masutani, H., Nakamura, H., Takagi, Y., Sono, H., Gon, Y., Yodoi, J., Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J. Biol. Chem. 274 (1999), 21645–21650.
56. [56] Patwari, P., Higgins, L.J., Chutkow, W.A., Yoshioka, J., Lee, R.T., The interaction of thioredoxin with Txnip. Evidence for formation of a mixed disulfide by disulfide exchange. J. Biol. Chem. 281 (2006), 21884–21891.
57. [57] Cadenas, C., Franckenstein, D., Schmidt, M., Gehrmann, M., Hermes, M., Geppert, B., Schormann, W., Maccoux, L.J., Schug, M., Schumann, A., Wilhelm, C., Freis, E., Ickstadt, K., Rahnenfuhrer, J., Baumbach, J.I., Sickmann, A., Hengstler, J.G., Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer. Breast Cancer Res.: BCR, 12, 2010, R44.
58. [58] Dutta, K.K., Nishinaka, Y., Masutani, H., Akatsuka, S., Aung, T.T., Shirase, T., Lee, W.H., Yamada, Y., Hiai, H., Yodoi, J., Toyokuni, S., Two distinct mechanisms for loss of thioredoxin-binding protein-2 in oxidative stress-induced renal carcinogenesis. Lab. Investig.; J. Tech. Methods Pathol. 85 (2005), 798–807.
59. [59] Kopantzev, E.P., Monastyrskaya, G.S., Vinogradova, T.V., Zinovyeva, M.V., Kostina, M.B., Filyukova, O.B., Tonevitsky, A.G., Sukhikh, G.T., Sverdlov, E.D., Differences in gene expression levels between early and later stages of human lung development are opposite to those between normal lung tissue and non-small lung cell carcinoma. Lung Cancer 62 (2008), 23–34.
60. [60] Yu, Y., Xing, K., Badamas, R., Kuszynski, C.A., Wu, H., Lou, M.F., Overexpression of thioredoxin-binding protein 2 increases oxidation sensitivity and apoptosis in human lens epithelial cells. Free Radic. Biol. Med. 57 (2013), 92–104.
61. [61] Yamaguchi, F., Takata, M., Kamitori, K., Nonaka, M., Dong, Y., Sui, L., Tokuda, M., Rare sugar D-allose induces specific up-regulation of TXNIP and subsequent G1 cell cycle arrest in hepatocellular carcinoma cells by stabilization of p27kip1. Int. J. Oncol. 32 (2008), 377–385.
62. [62] Fulda, S., Debatin, K.M., Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene 23 (2004), 6702–6711.
63. [63] C.R. Ireson, D.J. Jones, S. Orr, M.W. Coughtrie, D.J. Boocock, M.L. Williams, P.B. Farmer, W.P. Steward, A.J. Gescher, Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiology, Biomarkers and Prevention: a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, vol. 11, 2002, pp. 105–111.
64. [64] Wenzel, E., Somoza, V., Metabolism and bioavailability of trans-resveratrol. Mol. Nutr. Food Res. 49 (2005), 472–481.
65. [65] Yallapu, M.M., Khan, S., Maher, D.M., Ebeling, M.C., Sundram, V., Chauhan, N., Ganju, A., Balakrishna, S., Gupta, B.K., Zafar, N., Jaggi, M., Chauhan, S.C., Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer. Biomaterials 35 (2014), 8635–8648.
66. [66] Augustin, M.A., Sanguansri, L., Lockett, T., Nano- and micro-encapsulated systems for enhancing the delivery of resveratrol. Ann. N.Y. Acad. Sci. 1290 (2013), 107–112.